Gyre Therapeutics Inc Financials
Gyre Therapeutics Inc (GYRE) reported $116.6M in revenue for fiscal year 2025, up 10.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Profitability is positive, but cash conversion remains thin as liability-funded balance-sheet growth reshapes the business.
Between FY2024 and FY2025, operating margin compression took the measure from15.3% to9.9% even as revenue increased, showing that higher sales did not translate proportionally into operating earnings. Profits remained positive in both years, but operating cash flow shifted only from negative to positive while free cash flow stayed slightly negative, indicating improved yet incomplete cash realization.
Gross margin remained above 95% in FY2024 and FY2025, so the pressure occurred after product-level costs. SG&A rose from
The asset base jumped from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Gyre Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Gyre Therapeutics Inc has an operating margin of 9.8%, meaning the company retains $10 of operating profit per $100 of revenue. This below-average margin results in a low score of 29/100, suggesting thin profitability after operating expenses. This is down from 15.3% the prior year.
Gyre Therapeutics Inc's revenue grew 10.2% year-over-year to $116.6M, a solid pace of expansion. This earns a growth score of 36/100.
Gyre Therapeutics Inc has elevated debt relative to equity (D/E of 2.52), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 25/100, reflecting increased financial risk.
With a current ratio of 6.28, Gyre Therapeutics Inc holds $6.28 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 93/100.
While Gyre Therapeutics Inc generated $1.0M in operating cash flow, capex of $1.2M consumed most of it, leaving -$180K in free cash flow. This results in a low score of 33/100, reflecting heavy capital investment rather than weak cash generation.
Gyre Therapeutics Inc generates a 15.8% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 23/100. This is down from 28.3% the prior year.
Gyre Therapeutics Inc scores 3.37, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($708.3M) relative to total liabilities ($157.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Gyre Therapeutics Inc passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Gyre Therapeutics Inc generates $0.10 in operating cash flow ($1.0M OCF vs $9.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Gyre Therapeutics Inc earns $6.58 in operating income for every $1 of interest expense ($11.5M vs $1.7M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Gyre Therapeutics Inc generated $116.6M in revenue in fiscal year 2025. This represents an increase of 10.2% from the prior year.
Gyre Therapeutics Inc's EBITDA was $14.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 21.1% from the prior year.
Gyre Therapeutics Inc reported $9.9M in net income in fiscal year 2025. This represents a decrease of 44.8% from the prior year.
Gyre Therapeutics Inc earned $0.02 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 60.0% from the prior year.
Cash & Balance Sheet
Gyre Therapeutics Inc recorded an outflow of $180K in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 97.0% from the prior year.
Gyre Therapeutics Inc held $49.2M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Gyre Therapeutics Inc's gross margin was 95.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.0 percentage points from the prior year.
Gyre Therapeutics Inc's operating margin was 9.8% in fiscal year 2025, reflecting core business profitability. This is down 5.4 percentage points from the prior year.
Gyre Therapeutics Inc's net profit margin was 8.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 8.4 percentage points from the prior year.
Gyre Therapeutics Inc's ROE was 15.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 12.5 percentage points from the prior year.
Capital Allocation
Gyre Therapeutics Inc invested $13.7M in research and development in fiscal year 2025. This represents an increase of 13.9% from the prior year.
Gyre Therapeutics Inc invested $1.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 48.6% from the prior year.
Not reported for fiscal year 2025.
GYRE Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116.4M | $116.6M+10.2% | $105.8M-6.8% | $113.5M+10.9% | $102.3M+1294.0% | $7.3M-65.0% | $20.9M | N/A | $6K-99.4% | $1.0M | N/A | N/A | $275K-92.4% | $3.6M-93.7% | $57.9M-40.7% | $97.6M |
| Cost of Revenue | $6.8M | $5.4M+39.4% | $3.9M-16.2% | $4.6M-3.3% | $4.8M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $112.6M | $111.2M+9.1% | $101.9M-6.4% | $108.8M+11.6% | $97.5M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | $13.7M+13.9% | $12.0M-12.7% | $13.8M-17.4% | $16.7M-75.8% | $68.9M+30.0% | $53.0M+20.8% | $43.9M+104.2% | $21.5M+67.2% | $12.8M+11.2% | $11.6M+93.9% | $6.0M+13.1% | $5.3M-19.7% | $6.6M-86.6% | $49.1M-48.4% | $95.2M |
| SG&A Expenses | $23.7M | $20.8M+29.1% | $16.1M+9.9% | $14.7M-15.6% | $17.4M-8.4% | $19.0M+17.2% | $16.2M+20.6% | $13.4M+8.6% | $12.4M+23.6% | $10.0M+7.9% | $9.3M-3.5% | $9.6M+136.6% | $4.1M-0.8% | $4.1M-69.0% | $13.2M+8.4% | $12.2M |
| Operating Income | -$12.3M | $11.5M-28.9% | $16.2M+124.0% | -$67.2M-830.5% | $9.2M+110.5% | -$87.9M-53.2% | -$57.4M-0.2% | -$57.3M-69.3% | -$33.8M-55.0% | -$21.8M-6.9% | -$20.4M-47.9% | -$13.8M-83.8% | -$7.5M+25.8% | -$10.1M-24.4% | -$8.1M+16.5% | -$9.7M |
| Interest Expense | N/A | $1.7M+12.9% | $1.5M+48.2% | $1.0M+43.8% | $726K | N/A | N/A | N/A | N/A | N/A | N/A | $1.5M+6326.1% | $23K-56.6% | $53K-38.4% | $86K-34.8% | $132K |
| Income Tax | $3.5M | $4.6M-14.4% | $5.3M-37.5% | $8.5M+67.0% | $5.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $3.5M+49671.4% | $7K+106.9% | -$101K | $0 |
| Net Income | -$25.7M | $9.9M-44.8% | $17.9M+120.9% | -$85.5M-2081.5% | $4.3M+104.9% | -$87.9M-56.4% | -$56.2M-1.9% | -$55.2M-83.6% | -$30.1M-39.4% | -$21.6M-27.2% | -$16.9M-14.8% | -$14.8M-123.2% | -$6.6M+33.6% | -$10.0M-42.4% | -$7.0M+18.0% | -$8.5M |
| EPS (Diluted) | — | $0.02-60.0% | $0.05 | -$1.41 | $0.03 | -$2.87 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.21+22.2% | -$0.27 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GYRE Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $219.8M+75.2% | $125.4M+7.6% | $116.5M+37.5% | $84.8M+52.3% | $55.7M-41.3% | $94.8M-3.8% | $98.6M-21.1% | $124.9M+216.1% | $39.5M+3.7% | $38.1M-45.2% | $69.5M+2232.1% | $3.0M-43.5% | $5.3M-97.2% | $189.6M-26.6% | $258.1M |
| Current Assets | $149.4M+130.5% | $64.8M+13.2% | $57.2M+15.2% | $49.7M-3.5% | $51.5M-42.5% | $89.5M-6.8% | $96.1M-22.5% | $124.0M+217.0% | $39.1M+4.2% | $37.5M-45.4% | $68.7M+3218.7% | $2.1M-34.8% | $3.2M-97.5% | $127.7M-35.6% | $198.2M |
| Cash & Equivalents | $49.2M+316.4% | $11.8M-64.7% | $33.5M+33.1% | $25.2M-43.2% | $44.3M+46.1% | $30.4M+97.5% | $15.4M-50.8% | $31.2M+115.7% | $14.5M+41.0% | $10.3M-64.7% | $29.1M+1784.5% | $1.5M-45.4% | $2.8M-16.8% | $3.4M-96.8% | $107.3M |
| Inventory | $10.2M+60.5% | $6.3M+48.0% | $4.3M-30.1% | $6.1M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $31.1M+58.7% | $19.6M+29.2% | $15.2M | N/A | $1.8M-45.1% | $3.3M-77.9% | $15.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $157.3M+153.3% | $62.1M-53.1% | $132.4M+213.4% | $42.2M+189.8% | $14.6M-22.4% | $18.8M-37.9% | $30.2M+507.4% | $5.0M-43.1% | $8.7M-60.3% | $22.0M-42.2% | $38.1M-66.1% | $112.3M+3.7% | $108.3M-61.7% | $282.9M+237.5% | $83.8M |
| Current Liabilities | $23.8M+21.9% | $19.5M-2.6% | $20.0M+63.8% | $12.2M-13.6% | $14.2M-20.4% | $17.8M-38.4% | $28.9M+501.9% | $4.8M-45.1% | $8.7M-60.2% | $22.0M-41.8% | $37.8M+1516.3% | $2.3M+16.2% | $2.0M-82.3% | $11.3M-85.6% | $78.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% | $283K-75.1% | $1.1M-42.8% | $2.0M |
| Total Equity | $62.5M-1.3% | $63.3M+500.0% | -$15.8M-137.2% | $42.5M+3.5% | $41.1M-46.0% | $76.1M+11.3% | $68.3M-43.0% | $119.9M+289.8% | $30.8M+91.5% | $16.1M-48.9% | $31.4M+128.7% | -$109.4M-6.2% | -$103.0M-10.4% | -$93.3M-153.6% | $174.3M |
| Retained Earnings | -$112.6M-53.3% | -$73.5M+14.1% | -$85.5M-1256.7% | $7.4M+101.8% | -$402.7M-27.9% | -$314.8M-21.8% | -$258.5M-27.1% | -$203.3M-17.2% | -$173.5M-17.2% | -$148.0M-12.9% | -$131.0M-12.7% | -$116.3M-6.0% | -$109.7M+53.1% | -$233.9M-3.1% | -$226.9M |
Not reported in any period shown, so not listed: Goodwill.
GYRE Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.9M | $1.0M+127.7% | -$3.6M-114.1% | $25.9M+142.5% | $10.7M+112.7% | -$83.8M-52.1% | -$55.0M-26.2% | -$43.6M-52.7% | -$28.6M-43.2% | -$19.9M-7.9% | -$18.5M+3.4% | -$19.1M-199.2% | -$6.4M | N/A | -$64.2M+23.3% | -$83.7M |
| Capital Expenditures | $1.2M | $1.2M-48.6% | $2.3M-72.8% | $8.5M+70.9% | $5.0M+494.2% | $839K | N/A | $64K-83.0% | $376K+1534.8% | $23K-95.1% | $468K+72.1% | $272K+6700.0% | $4K-90.2% | $41K-87.7% | $333K-76.7% | $1.4M |
| Free Cash Flow | -$6.1M | -$180K+97.0% | -$6.0M-134.3% | $17.4M+205.3% | $5.7M+106.7% | -$84.6M | N/A | -$43.7M-51.0% | -$28.9M-44.9% | -$20.0M-5.4% | -$18.9M+2.3% | -$19.4M-203.3% | -$6.4M | N/A | -$64.6M+24.2% | -$85.1M |
| Investing Cash Flow | $2.9M | -$474K+97.6% | -$19.9M-0.6% | -$19.8M-43.0% | -$13.8M-128.7% | $48.2M+398.7% | $9.7M-64.7% | $27.4M+138.4% | -$71.3M-537.1% | -$11.2M | N/A | N/A | N/A | $13.4M-66.3% | $39.8M+169.1% | -$57.7M |
| Financing Cash Flow | $2.8M | $24.4M+1059.8% | $2.1M-15.9% | $2.5M+105.6% | -$45.0M-190.8% | $49.6M-17.9% | $60.4M+18363.6% | $327K-99.7% | $111.3M+428.1% | $21.1M | N/A | N/A | N/A | -$552K+11.8% | -$626K-100.8% | $82.8M |
| Dividends Paid | N/A | N/A | N/A | N/A | $45.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $82K | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
GYRE Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.3%-1.0pp | 96.3%+0.4pp | 95.9%+0.6pp | 95.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 9.8%-5.4pp | 15.3%+74.5pp | -59.3%-68.3pp | 9.0% | -1197.8% | -273.9% | N/A | -563700.0% | -2143.6% | N/A | N/A | -2730.5% | -278.9% | -14.1%-4.1pp | -10.0% |
| Net Margin | 8.5%-8.4pp | 16.9%+92.3pp | -75.3%-79.6pp | 4.2% | -1198.3% | -268.5% | N/A | -500916.7% | -2118.0% | N/A | N/A | -2404.7% | -274.6% | -12.1%-3.3pp | -8.7% |
| Return on Equity | 15.8%-12.5pp | 28.3% | N/A | 10.2%+224.2pp | -214.0%-140.1pp | -73.9%+6.8pp | -80.8%-55.7pp | -25.1%+45.0pp | -70.1%+35.4pp | -105.4%-58.5pp | -47.0% | N/A | N/A | N/A | -4.9% |
| Return on Assets | 4.5%-9.8pp | 14.3%+87.6pp | -73.4%-78.4pp | 5.1%+163.1pp | -158.0%-98.7pp | -59.3%-3.3pp | -56.0%-31.9pp | -24.1%+30.5pp | -54.6%-10.1pp | -44.5%-23.3pp | -21.2%+200.6pp | -221.8%-32.9pp | -189.0%-185.3pp | -3.7%-0.4pp | -3.3% |
| Current Ratio | 6.28+3.0x | 3.32+0.5x | 2.85-1.2x | 4.06+0.4x | 3.63-1.4x | 5.03+1.7x | 3.32-22.5x | 25.83+21.4x | 4.48+2.8x | 1.71-0.1x | 1.82+0.9x | 0.89-0.7x | 1.58-9.7x | 11.26+8.7x | 2.52 |
| Debt-to-Equity | 2.52+1.5x | 0.98 | N/A | 0.99+0.6x | 0.35+0.1x | 0.25-0.2x | 0.44+0.4x | 0.04-0.2x | 0.28-1.1x | 1.37+0.2x | 1.21 | N/A | N/A | N/A | 0.01 |
| FCF Margin | -0.1%+5.5pp | -5.6%-21.0pp | 15.3%+9.8pp | 5.6% | -1152.8% | N/A | N/A | -482150.0% | -1961.0% | N/A | N/A | -2324.7% | N/A | -111.6% | -87.2% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Gyre Therapeutics Inc Ranks
Frequently Asked Questions
What is Gyre Therapeutics Inc's annual revenue?
Gyre Therapeutics Inc (GYRE) reported $116.6M in total revenue for fiscal year 2025. This represents a 10.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Gyre Therapeutics Inc's revenue growing?
Gyre Therapeutics Inc (GYRE) revenue grew by 10.2% year-over-year, from $105.8M to $116.6M in fiscal year 2025.
Is Gyre Therapeutics Inc profitable?
Yes, Gyre Therapeutics Inc (GYRE) reported a net income of $9.9M in fiscal year 2025, with a net profit margin of 8.5%.
What is Gyre Therapeutics Inc's EBITDA?
Gyre Therapeutics Inc (GYRE) had EBITDA of $14.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Gyre Therapeutics Inc's gross margin?
Gyre Therapeutics Inc (GYRE) had a gross margin of 95.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Gyre Therapeutics Inc's operating margin?
Gyre Therapeutics Inc (GYRE) had an operating margin of 9.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Gyre Therapeutics Inc's net profit margin?
Gyre Therapeutics Inc (GYRE) had a net profit margin of 8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Gyre Therapeutics Inc's return on equity (ROE)?
Gyre Therapeutics Inc (GYRE) has a return on equity of 15.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Gyre Therapeutics Inc's free cash flow?
Gyre Therapeutics Inc (GYRE) recorded an outflow of $180K in free cash flow during fiscal year 2025. This represents a 97.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Gyre Therapeutics Inc's operating cash flow?
Gyre Therapeutics Inc (GYRE) generated $1.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Gyre Therapeutics Inc's total assets?
Gyre Therapeutics Inc (GYRE) had $219.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Gyre Therapeutics Inc's capital expenditures?
Gyre Therapeutics Inc (GYRE) invested $1.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Gyre Therapeutics Inc spend on research and development?
Gyre Therapeutics Inc (GYRE) invested $13.7M in research and development during fiscal year 2025.
What is Gyre Therapeutics Inc's current ratio?
Gyre Therapeutics Inc (GYRE) had a current ratio of 6.28 as of fiscal year 2025, which is generally considered healthy.
What is Gyre Therapeutics Inc's debt-to-equity ratio?
Gyre Therapeutics Inc (GYRE) had a debt-to-equity ratio of 2.52 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Gyre Therapeutics Inc's return on assets (ROA)?
Gyre Therapeutics Inc (GYRE) had a return on assets of 4.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Gyre Therapeutics Inc's Altman Z-Score?
Gyre Therapeutics Inc (GYRE) has an Altman Z-Score of 3.37, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Gyre Therapeutics Inc's Piotroski F-Score?
Gyre Therapeutics Inc (GYRE) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Gyre Therapeutics Inc's earnings high quality?
Gyre Therapeutics Inc (GYRE) has an earnings quality ratio of 0.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Gyre Therapeutics Inc cover its interest payments?
Gyre Therapeutics Inc (GYRE) has an interest coverage ratio of 6.58x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Gyre Therapeutics Inc?
Gyre Therapeutics Inc (GYRE) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.